Biomimetic membrane technologies for Alzheimer's drug discovery

NeuroMimesys

A controlled experimental environment to generate interpretable functional information

NeuroMimesys is designed as a non-cellular biomimetic experimental environment for the study of selected membrane-level molecular events relevant to Alzheimer's disease, with reference to membrane processes connected to APP biology, secretases, and the generation of β-amyloid oligomers.

The platform does not replace cellular or animal models. It is designed to complement them by providing a more controllable and interpretable experimental layer for early-stage drug discovery.

Why it matters

A biomimetic membrane system is designed to reduce biological complexity, isolate specific membrane variables, and generate measurable functional responses.

The objective is to support earlier and more informed decisions by providing an additional and complementary experimental layer between simplified biophysical models and subsequent stages of cellular, animal, and industrial validation.

Development and collaborations

The development of NeuroMimesys is supported by a biomimetic membrane technology base and an intellectual property portfolio with international protection.

Biomimesi is open to engaging with investors, industrial partners, pharmaceutical companies, biotech firms, and scientific collaborators interested in the next phases of platform development.